
    
      A multi-centre, open label, phase IIb study, evaluating the safety, tolerability and efficacy
      of a targeted intraprostatic focal administration in development. The study will treat
      approximately 40 men who meet the eligibility criteria, and give written consent. Safety and
      tolerability will be assessed post-treatment over 26 weeks. Efficacy will be assessed by
      biopsy and imaging (mpMRI) at 24 weeks.
    
  